See more : AhnLab, Inc. (053800.KQ) Income Statement Analysis – Financial Results
Complete financial analysis of ALX Oncology Holdings Inc. (ALXO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ALX Oncology Holdings Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- APA Corporation (0HGC.L) Income Statement Analysis – Financial Results
- The Toronto-Dominion Bank (0VL8.L) Income Statement Analysis – Financial Results
- Anhui Gujing Distillery Co., Ltd. (000596.SZ) Income Statement Analysis – Financial Results
- Fuji Die Co.,Ltd. (6167.T) Income Statement Analysis – Financial Results
- Investeringsforeningen Maj Invest – Value Aktier Sri+ Kl (MAJGANF.CO) Income Statement Analysis – Financial Results
ALX Oncology Holdings Inc. (ALXO)
About ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors. The company's pre-clinical products include ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was founded in 2015 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 1.18M | 4.80M | 2.07M |
| Cost of Revenue | 836.00K | 1.47M | 736.00K | 1.08M | 4.36M | 1.88M |
| Gross Profit | -836.00K | -1.47M | -736.00K | 107.00K | 436.00K | 187.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 9.05% | 9.09% | 9.05% |
| Research & Development | 141.80M | 98.40M | 60.17M | 28.96M | 16.31M | 11.27M |
| General & Administrative | 28.48M | 29.04M | 23.39M | 14.81M | 3.31M | 2.60M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 28.48M | 29.04M | 23.39M | 14.81M | 3.31M | 2.60M |
| Other Expenses | 0.00 | -260.00K | 84.00K | -404.00K | -5.00K | -2.00K |
| Operating Expenses | 170.28M | 127.44M | 83.56M | 43.77M | 19.62M | 13.87M |
| Cost & Expenses | 170.28M | 127.44M | 83.56M | 44.85M | 23.98M | 15.75M |
| Interest Income | 10.65M | 4.04M | 91.00 | 124.00K | 21.00 | 0.00 |
| Interest Expense | 1.57M | 0.00 | 13.00K | 811.00K | 21.00K | 0.00 |
| Depreciation & Amortization | 836.00K | 1.47M | 736.00K | 202.00K | 429.00K | 431.00K |
| EBITDA | -158.40M | -121.95M | -83.47M | -43.46M | -18.76M | -13.26M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -3,728.17% | -391.14% | -641.27% |
| Operating Income | -170.28M | -127.44M | -83.56M | -43.66M | -19.18M | -13.68M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -3,693.99% | -399.98% | -662.02% |
| Total Other Income/Expenses | 9.47M | 4.02M | 71.00K | -1.84M | -26.00K | -2.00K |
| Income Before Tax | -160.81M | -123.42M | -83.48M | -45.50M | -19.21M | -13.69M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -3,849.32% | -400.52% | -662.12% |
| Income Tax Expense | 0.00 | 64.00K | -21.00K | 241.00K | 34.00K | 45.00K |
| Net Income | -160.81M | -123.48M | -83.46M | -45.74M | -19.24M | -13.73M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -3,869.71% | -401.23% | -664.30% |
| EPS | -3.74 | -3.03 | -2.07 | -1.15 | -0.53 | -0.63 |
| EPS Diluted | -3.74 | -3.03 | -2.07 | -1.15 | -0.53 | -0.63 |
| Weighted Avg Shares Out | 42.99M | 40.70M | 40.31M | 39.84M | 36.49M | 21.95M |
| Weighted Avg Shares Out (Dil) | 42.99M | 40.70M | 40.31M | 39.84M | 36.49M | 21.95M |
ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
ALX Oncology Realigns Executive Leadership Team
ALX Oncology Announces September Investor Conference Participation
ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update
ALX Oncology Holdings Inc. (ALXO) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
ALX Oncology Holdings Inc. (ALXO) Loses -18.84% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference
ALX Oncology Announces Upcoming Investor Conference Participation
ALX Oncology Announces Upcoming Investor Conference Participation
Source: https://incomestatements.info
Category: Stock Reports